OKLAHOMA Health Care Authority | Serving Oklahomans through SoonerCare

October 28, 2024

RE: Coverage Changes to Herzuma® – Effective November 11, 2024

Effective November 11, 2024, Herzuma® (trastuzumab-pkrb) will no longer be a preferred trastuzumab product. SoonerCare members currently on therapy with Herzuma® will be approved for continuation of therapy. Requests for new starts will need to use a preferred trastuzumab product.

The preferred trastuzumab products include:

- Kanjinti® (trastuzumab-anns); and
- Trazimera® (trastuzumab-qyyp)

The specific prior authorization (PA) requirements for Herzuma® and other trastuzumab products can be found in the "Oncologic Therapies" therapeutic category on the OHCA website at www.oklahoma.gov/ohca/pa. The trastuzumab product PA form, PHARM-133, is located on the OHCA website at www.oklahoma.gov/ohca/rxforms.

Thank you for the services you provide to Oklahomans insured by SoonerCare!

ADDRESS
4345 N. Lincoln Blvd.
Oklahoma City, OK 73105

WEBSITES
oklahoma.gov/ohca
mysoonercare.org

PHONE
Admin: 405-522-7300
Helpline: 800-987-7767